OncoResponse: Funding, Investors & Team (Oct 2026)
OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology. OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.
OncoResponse has raised $14.0M across 1 funding round on record, the most recent an undisclosed round of $14.0M announced in May 2023.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
OncoResponse Company Profile and Key Stats
Latest funding round on record: May 2023.
OncoResponse Funding Rounds
OncoResponse Founders and Leadership Team
No contact details are on record for this team yet.
OncoResponse Funding Compared to Other Biotechnology Startups
OncoResponse's latest round of $14.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like OncoResponse in Biotechnology and Seattle
Companies Similar to OncoResponse
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
OncoResponse Funding FAQs
What does OncoResponse do?
OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology. OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.
How much funding has OncoResponse raised?
OncoResponse has raised $14.0M across 1 round on record. The most recent is an undisclosed round of $14.0M announced in May 2023.
When did OncoResponse last raise funding?
OncoResponse's most recent funding round on record is an undisclosed round of $14.0M, announced in May 2023.
Who is the CEO of OncoResponse?
Clifford J Stocks is listed as CEO at OncoResponse.
Where is OncoResponse headquartered?
OncoResponse is based in Seattle, Washington, United States.
How many employees does OncoResponse have?
OncoResponse is in the 11-50 employee band.
How does OncoResponse's funding compare to other Biotechnology startups?
OncoResponse's latest round of $14.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's OncoResponse Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for OncoResponse is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.